Bicocca Open Archive

Logo unimib boa
CARBONE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.578
EU - Europa 10.673
AS - Asia 10.263
SA - Sud America 1.577
Continente sconosciuto - Info sul continente non disponibili 922
AF - Africa 265
OC - Oceania 20
Totale 43.298
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.463
SG - Singapore 3.674
IT - Italia 3.238
SE - Svezia 2.587
CN - Cina 1.959
HK - Hong Kong 1.392
VN - Vietnam 1.360
RU - Federazione Russa 1.189
BR - Brasile 1.146
DE - Germania 1.041
CA - Canada 872
IE - Irlanda 621
GB - Regno Unito 516
BD - Bangladesh 414
FR - Francia 351
IN - India 313
KR - Corea 171
NL - Olanda 167
AT - Austria 162
AR - Argentina 157
TR - Turchia 155
UA - Ucraina 141
FI - Finlandia 132
IQ - Iraq 122
ID - Indonesia 120
CH - Svizzera 100
ES - Italia 95
MX - Messico 89
PL - Polonia 87
JP - Giappone 85
ZA - Sudafrica 81
PK - Pakistan 78
EC - Ecuador 72
PH - Filippine 72
DK - Danimarca 64
VE - Venezuela 54
CO - Colombia 53
SA - Arabia Saudita 51
MY - Malesia 49
JM - Giamaica 41
UZ - Uzbekistan 34
MA - Marocco 33
EG - Egitto 27
BE - Belgio 25
CR - Costa Rica 25
JO - Giordania 24
LT - Lituania 24
CL - Cile 23
PY - Paraguay 23
DZ - Algeria 21
AZ - Azerbaigian 20
KE - Kenya 20
IL - Israele 19
PT - Portogallo 19
ET - Etiopia 18
RO - Romania 18
TW - Taiwan 18
AE - Emirati Arabi Uniti 17
BO - Bolivia 17
NP - Nepal 17
TT - Trinidad e Tobago 16
PE - Perù 15
TH - Thailandia 15
TN - Tunisia 15
AU - Australia 14
CZ - Repubblica Ceca 14
HN - Honduras 14
UY - Uruguay 14
RS - Serbia 12
OM - Oman 11
PS - Palestinian Territory 11
AL - Albania 10
BG - Bulgaria 10
GT - Guatemala 9
PA - Panama 9
SN - Senegal 9
SY - Repubblica araba siriana 9
GR - Grecia 8
KZ - Kazakistan 7
SK - Slovacchia (Repubblica Slovacca) 7
AO - Angola 6
CI - Costa d'Avorio 6
DO - Repubblica Dominicana 6
IR - Iran 6
BY - Bielorussia 5
EE - Estonia 5
HU - Ungheria 5
LA - Repubblica Popolare Democratica del Laos 5
MM - Myanmar 5
NI - Nicaragua 5
PR - Porto Rico 5
SV - El Salvador 5
BA - Bosnia-Erzegovina 4
CG - Congo 4
GD - Grenada 4
GE - Georgia 4
GH - Ghana 4
LB - Libano 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
Totale 42.301
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.274
Singapore 2.002
Ashburn 1.899
Stockholm 1.896
Hong Kong 1.342
San Jose 1.236
Milan 1.011
Frankfurt am Main 756
Toronto 650
Fairfield 634
Council Bluffs 615
Dublin 598
Chandler 570
New York 509
Chicago 490
Woodbridge 488
Wilmington 483
Santa Clara 433
Houston 416
Ho Chi Minh City 414
Los Angeles 403
Dallas 380
Hanoi 332
Rome 322
Hefei 296
Seattle 282
Beijing 266
Dearborn 252
The Dalles 227
Cambridge 225
Princeton 224
Boardman 184
Buffalo 159
Lauterbourg 159
London 158
Jacksonville 156
Seoul 153
Shanghai 140
Columbus 138
Vienna 127
São Paulo 116
Nanjing 111
Moscow 105
Lawrence 104
Altamura 101
Phoenix 96
Zurich 84
Orem 79
San Diego 79
Turin 79
Munich 71
Denver 67
Jakarta 67
Helsinki 65
Tokyo 61
Warsaw 56
Atlanta 55
Brooklyn 55
Figino 55
Florence 55
Montreal 50
Haiphong 48
Monza 48
Nuremberg 48
Baghdad 47
Rio de Janeiro 45
Naples 44
Johannesburg 43
Da Nang 42
Boston 40
San Francisco 39
Washington 38
Salt Lake City 37
Bari 35
Bologna 34
Paris 34
Guangzhou 33
Amsterdam 32
Genoa 32
Mumbai 32
Biên Hòa 31
Chennai 30
Andover 29
Lachine 29
Kingston 28
Lissone 28
Manchester 28
Pune 28
Tashkent 28
Nanchang 27
Poplar 27
Tianjin 27
Biloxi 25
Charlotte 25
Ottawa 25
Quito 25
Guayaquil 24
Hải Dương 24
Hangzhou 23
Istanbul 23
Totale 26.195
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 2.029
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 638
The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 498
Exploring the landscape of steatotic liver disease in the general US population 462
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 458
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 444
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 421
Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid 410
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement 402
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 396
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 393
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 385
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 377
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 377
Endocrinology and Metabolic Diseases (Including Diabetes) 376
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 372
Risk stratification in primary sclerosing cholangitis 366
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 362
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 362
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 361
Autoimmune liver disease, autoimmunity and liver transplantation 360
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 354
Precision medicine in primary biliary cholangitis 354
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 343
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 342
Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation 334
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 322
Autoimmune liver diseases 321
New Therapeutic Targets in Autoimmune Cholangiopathies 321
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 317
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 316
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 316
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 312
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 308
Artificial Intelligence and liver: Opportunities and barriers 304
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 303
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis 298
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 297
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 297
An update on novel pharmacological agents for primary sclerosing cholangitis 296
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 294
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? 291
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 289
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 288
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 287
Artificial intelligence for precision medicine in autoimmune liver disease 283
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 283
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 282
The challenges of primary biliary cholangitis: What is new and what needs to be done 276
Prognostic models in primary biliary cholangitis 271
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 271
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 269
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 269
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 269
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score 266
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 260
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 257
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 256
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 256
Non-invasive imaging biomarkers in chronic liver disease 255
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 253
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 252
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 250
Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study 250
Steroid-loaded Avidin-Nucleic-Acid-Nano-Assemblies reduce hepatic fibrosis modulating Kupffer cells in primary biliary cholangitis 249
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 249
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 248
Comprehensive review of autoantibodies in patients with hyper-IgM syndrome 248
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 246
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 246
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 246
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 243
Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence? 242
Genetics and epigenetics of primary biliary cirrhosis 241
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 241
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 238
The phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants 238
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 236
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 234
The immunobiology of female predominance in primary biliary cholangitis 230
Diagnostic Yield of Whole Exome Sequencing in Adult-onset Cholestatic Liver Disease 227
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 224
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 223
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 221
Hepatitis C virus and nonliver solid organ transplantation 220
Leptin attenuates ischemia-reperfusion injury in the rat liver 219
Cell and organ bioengineering technology as applied to gastrointestinal diseases 218
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis 216
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 216
Open challenges in the management of autoimmune hepatitis 212
Treatment discontinuation with peg-interferon: What to consider 212
Intensive care management of acute-on-chronic liver failure 212
European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care 209
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 208
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis 208
Late acute liver allograft rejection; A study of its natural history and graft survival in the current era 207
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 206
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort 206
Cost of illness of Primary Biliary Cholangitis - a population-based study 206
Automating liver biopsy segmentation with a robust, open-source tool for pathology research: the HOTSPoT model 205
Totale 30.931
Salva come PNG Salva come JPEG
Categoria #
all - tutte 140.514
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.277 0 0 0 143 141 142 54 105 79 145 170 298
2022/20232.934 333 740 266 252 264 370 126 130 222 76 83 72
2023/20242.687 71 111 108 258 293 580 383 76 156 173 93 385
2024/20256.364 445 717 389 347 506 216 322 290 669 813 685 965
2025/202617.713 1.534 958 1.171 1.569 1.502 792 2.095 867 1.300 3.327 1.202 1.396
2026/20275.652 704 1.147 1.968 1.833 0 0 0 0 0 0 0 0
Totale 43.298